Qing-feng Xiang, Dong-Mei Zhang, Jing-nan Wang
Mar 1, 2015
Citations
4
Influential Citations
49
Citations
Quality indicators
Journal
Liver International
Abstract
Cabozantinib, a small‐molecule multitargeted tyrosine kinase inhibitor, has entered into a phase III clinical trial for the treatment of hepatocellular carcinoma (HCC). This study assessed the mechanistic effect of cabozantinib on the reversal of P‐glycoprotein (P‐gp)‐mediated multidrug resistance (MDR).